Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Immix Biopharma (NASDAQ: IMMX)

Last close As at 23/11/2024

USD1.68

▲ −0.14 (−7.69%)

Market capitalisation

USD47m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

CAR-T cell therapies have the potential to provide effective treatments for challenging diseases. However, current available options are not considered outpatient treatments due to the risk of serious side effects. If NXC-201 continues to demonstrate a desirable efficacy and safety profile, it could become the first outpatient CAR-T cell therapy.

Latest Insights

View More

Healthcare | Flash note

Immix Biopharma — US CAR-T trial progresses to dose expansion

Healthcare | Update

Immix Biopharma — Full steam ahead with US CAR-T trial

Healthcare | Flash note

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

Healthcare | Flash note

Immix Biopharma — US CAR-T trial commences patient dosing
Scientist using protective robber gloves for handling substances and experiments
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Balance Sheet

Forecast net debt (US$m)

15.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 5.8 (16.1) (58.7)
Relative 4.9 (20.7) (68.3)
52 week high/low US$7.3/US$1.3

Financials

Immix Biopharma is a clinical-stage biopharmaceutical company focused on the development of novel cell therapies. Lead sterically-optimized CAR-T candidate NXC-201 is being assessed in the potentially pivotal US-based NEXICART-2 trial in relapsed/refractory AL amyloidosis (ALA); this is now in the dose expansion stage and initial data are expected in Q424. Historically, NXC-201 has been assessed in the Phase Ib/IIa NEXICART-1 trial for multiple myeloma and ALA. Rolling data readouts demonstrated high response rates and a desirable safety profile in both indications. An announcement on expansion to immune-mediated diseases is expected by end-2025. NXC-201 has been awarded Orphan Drug Designation in ALA by the US FDA and in the EU by the EMA.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2022A 0.0 (8.2) (7.6) (54.77) N/A N/A
2023A 0.0 (16.1) (13.0) (75.14) N/A N/A
2024E 2.0 (19.9) (16.6) (60.55) N/A N/A
2025E 6.0 (20.1) (17.1) (58.22) N/A N/A

Research

Cancer cells low poly blue

Update

Healthcare

Immix Biopharma — Full steam ahead with US CAR-T trial

Flash note

Healthcare

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

Healthcare

Flash note

Immix Biopharma — US CAR-T trial progresses to dose expansion
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free